Branded

SB 159 authorizes pharmacists to prescribe PrEP and PEP to patient without a physician prescription and prohibits insurance companies from requiring patients to obtain prior authorization before using their insurance benefits to obtain PrEP or PEP.

Roche's Rituxan now is the first and only FDA approved treatment for pediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis.

Galderma's Aklief (trifarotene cream) is the first new retinoid molecule to receive FDA approval for the treatment of acne in more than 20 years

AstraZeneca's Fasenra is the only respiratory biologic that offers the choice of administration at home or in a doctor’s office with eight-week maintenance dosing, the company said.

Tosymra is the third product in Upsher-Smith's migraine portfolio.

Temixys, which the Food and Drug Administration approved last November, is indicated as a single-tablet regimen to treat HIV in combination with other antiretroval agents. 

Mavyret is now the first eight-week treatment approved for all treatment-naïve adult and certain pediatric patients with HCV genotypes 1-6 both without cirrhosis and with compensated cirrhosis.

Descovy is the second FDA approved to prevent HIV infection.

Novo Nordisk’s Rybelsus is the first GLP-1 analog treatment available in a pill for adults with Type 2 diabetes.

Bavarian Nordic's Jynneos, is the first live, non-replicating vaccine to prevent smallpox and monkeypox.

Ardelyx's Ibsrela is a twice-daily oral pill for IBS-C in adults.

The FDA has approved the third indication for Eli Lilly's Taltz.